Comparative Pharmacology
Head-to-head clinical analysis: AEROSPORIN versus BLEPH 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEROSPORIN versus BLEPH 10.
AEROSPORIN vs BLEPH-10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Polymyxin B binds to the lipid A portion of bacterial lipopolysaccharides, disrupting the outer membrane permeability and causing bacterial cell death. It is primarily active against Gram-negative bacteria.
Sulfacetamide is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking the conversion of p-aminobenzoic acid (PABA) to dihydrofolate, thereby inhibiting bacterial folic acid synthesis and exerting bacteriostatic activity.
Polymyxin B sulfate: 1.5-2.5 mg/kg/day intravenously divided every 12 hours, or 25,000-30,000 units/kg/day intramuscularly divided every 12 hours. Ophthalmic: 1-2 drops in affected eye every 4 hours. Topical: Apply to affected area 3-4 times daily.
Instill 1-2 drops into the conjunctival sac every 3-4 hours, initially up to every 2 hours for severe infections.
None Documented
None Documented
Terminal elimination half-life is approximately 2-3 hours in adults with normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <10 mL/min), necessitating dose adjustment.
Terminal elimination half-life is 60-90 minutes in patients with normal renal function; prolonged in renal impairment.
Primarily renal excretion of unchanged drug via glomerular filtration. Approximately 60-70% of an intravenous dose is recovered in urine within 24 hours; minimal biliary/fecal elimination (<5%).
Renal excretion of unchanged drug accounts for approximately 50-70% of the dose; biliary/fecal excretion is minimal (<10%).
Category C
Category C
Ophthalmic Antibiotic
Ophthalmic Antibiotic